PE20010679A1 - Uso de inhibidores de secrecion de apolipoproteinas b y/o de proteina de transferencia de trigliceridos microsomales - Google Patents

Uso de inhibidores de secrecion de apolipoproteinas b y/o de proteina de transferencia de trigliceridos microsomales

Info

Publication number
PE20010679A1
PE20010679A1 PE2000001184A PE0011842000A PE20010679A1 PE 20010679 A1 PE20010679 A1 PE 20010679A1 PE 2000001184 A PE2000001184 A PE 2000001184A PE 0011842000 A PE0011842000 A PE 0011842000A PE 20010679 A1 PE20010679 A1 PE 20010679A1
Authority
PE
Peru
Prior art keywords
apolipoprotein
microsomal
transfer protein
triglycerid
cyane
Prior art date
Application number
PE2000001184A
Other languages
English (en)
Spanish (es)
Inventor
Kristin Marie Lundy
Bradley Paul Morgan
Mary Anne Hickman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010679A1 publication Critical patent/PE20010679A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2000001184A 1999-11-10 2000-11-07 Uso de inhibidores de secrecion de apolipoproteinas b y/o de proteina de transferencia de trigliceridos microsomales PE20010679A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16451399P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
PE20010679A1 true PE20010679A1 (es) 2001-06-30

Family

ID=22594839

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001184A PE20010679A1 (es) 1999-11-10 2000-11-07 Uso de inhibidores de secrecion de apolipoproteinas b y/o de proteina de transferencia de trigliceridos microsomales

Country Status (11)

Country Link
EP (1) EP1099438A3 (OSRAM)
JP (1) JP2001181209A (OSRAM)
KR (1) KR100439384B1 (OSRAM)
AU (1) AU777542B2 (OSRAM)
CA (1) CA2325282C (OSRAM)
CO (1) CO5271688A1 (OSRAM)
HU (1) HUP0004454A3 (OSRAM)
IL (1) IL139449A0 (OSRAM)
NZ (1) NZ508061A (OSRAM)
PE (1) PE20010679A1 (OSRAM)
ZA (1) ZA200006417B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EA010369B1 (ru) 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
ES2799404T3 (es) 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
PT902785E (pt) * 1996-04-30 2002-12-31 Pfizer Processos e intermediarios de preparacao de ¬2-(2h-¬1,2,4|triazol-3-ilmetil)-1,2,3,4-tetra-hidro-isoquinolin-6-il|-amida de acido 4'-trifluorometilbifenil-2-carboxilico
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
TR199901180T2 (xx) * 1996-11-27 1999-08-23 Pfizer Inc. Apo B-Salg�lama/MTP inhibit�r amidler.
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
IL133201A0 (en) * 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)

Also Published As

Publication number Publication date
EP1099438A2 (en) 2001-05-16
EP1099438A3 (en) 2003-03-19
HUP0004454A3 (en) 2004-04-28
HU0004454D0 (OSRAM) 2001-01-29
KR20010051509A (ko) 2001-06-25
ZA200006417B (en) 2002-05-08
NZ508061A (en) 2002-04-26
CA2325282C (en) 2005-12-06
IL139449A0 (en) 2001-11-25
CA2325282A1 (en) 2001-05-10
JP2001181209A (ja) 2001-07-03
AU7151900A (en) 2001-05-17
HUP0004454A2 (hu) 2001-10-28
AU777542B2 (en) 2004-10-21
CO5271688A1 (es) 2003-04-30
KR100439384B1 (ko) 2004-07-09

Similar Documents

Publication Publication Date Title
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
EA200201214A1 (ru) Замещенные тиоацетамиды
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
DE60112897D1 (de) Stabilisierung von implantierbarem bioprothesegewebe
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA200400648A1 (ru) N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
DE60237696D1 (de) Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
DE60336014D1 (de) Pyrrolobenzodiazepine zur behandlung proliferativer erkrankungen
EA200400586A1 (ru) Замещённые тиоацетамиды
CO5611065A2 (es) Difluorometiltiazolilcarboxanilidas
EA200600525A1 (ru) Еро-имитирующие миметичекие антитела человека с центральной шарнирной областью, композиции, способы и применения
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
ATE396993T1 (de) Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
ES2060591T5 (es) Compuestos pirazolotriazina.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
MXPA03010586A (es) N-[(1s)-1,2,3,4-tertrahidro-1-naftalenil benzamidas trisubtituidas, las cuales inhiben receptores que contienen p2x2/3.
DK1383874T3 (da) Varianter af lipogygenase og deres anvendelse
NO995963D0 (no) Karboksamider anvendelige som 5-HTIF-agonister
DE60325377D1 (de) Motilidverbindungen
EA200200948A1 (ru) Лечение псориаза
IL157495A0 (en) Method for the production of d-panthothenic acid and/or salts thereof as adjunct for animal feedstuffs

Legal Events

Date Code Title Description
FC Refusal